On the Question of the Tumoricidal Dose in Non-Hodgkin’s Lymphomas

Musshoff, K.; Leopold, Howard C.

doi:10.1007/978-3-642-81249-1_25

Cited by 8 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, lower doses (36 to 44 Gy) were used in NHL of low-grade malignancy than in NHL of high-grade malignancy (at least 45 Gy). In centroblastic-centrocytic (CB-CC) lymphoma which had been proved to be particularly radiosensitive (Cox et al, 1974;Musshoff and Leopold, 1978) doses of only 25 Gy were applied. Since the majority of stage III lymphomas had to be considered potentially generalized, these patients (except for CB-CC lymphoma; see below) were treated like patients with stage IV with chemotherapy and adjuvant irradiation of at least the remnant lymphomas and/or extranodal manifestations.…”

Section: Treatmentmentioning

confidence: 99%

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Brittinger¹,

Bartels

Common³

et al. 1984

Hematological Oncology

Self Cite

203

View full text Add to dashboard Cite

Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas (NHL) was investigated in 1127 patients entering a prospective multicenter observation study. Survival of the 782 (69.4 per cent) patients with low-grade malignant NHL (lymphocytic lymphomas, predominantly B-CLL, LP immunocytoma, centrocytic lymphoma, centroblastic-centrocytic lymphoma) exceeded that of the 341 patients (30.2 per cent) with high-grade malignant NHL (centroblastic, immunoblastic, lymphoblastic lymphomas). Prognosis was best in centroblastic-centrocytic lymphoma and in B-CLL and least favorable in immunoblastic and lymphoblastic lymphomas. Survival of LP immunocytoma and centrocytic lymphoma patients was intermediate after 2 to 2.5 years of follow-up. Corresponding to histopathology, pattern of survival curves of low-grade malignant NHL (slow decline, no plateauing) differed from that of high-grade malignant NHL (rapid decline, subsequent plateauing). Prognosis of B-CLL was superior to that of LP immunocytoma. Stages I and II were more frequent in centroblastic-centrocytic lymphoma (21 per cent) than in LP immunocytoma (2.5 per cent) and centrocytic lymphoma (11 per cent). Ability of radiotherapy to induce stable complete remissions in stage III of centroblastic-centrocytic lymphoma indicates prolonged restriction of lymphoma to the lymphatic system. In immunoblastic and centroblastic lymphomas, stages I and II were diagnosed in 34 and 38 per cent of cases, respectively, but only in stage I/IE of centroblastic lymphoma prolonged remissions were achieved by radiotherapy. In advanced high-grade malignant NHL marked improvement of prognosis was solely possible by induction of complete remissions whereas in corresponding low-grade malignant lymphomas also partial remissions were prognostically relevant.

show abstract

Section: Treatmentmentioning

confidence: 99%

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Brittinger¹,

Bartels

Common³

et al. 1984

Hematological Oncology

Self Cite

203

View full text Add to dashboard Cite

show abstract

“…However, the 10-year relapse-free survival rate was 50-80%, in accordance with the prognostic factors and staging accuracy, with or without laparotomy (12), in the era before computed tomography (Table 1) (8,10,(12)(13)(14)(15)(16) . Nevertheless, in the ''old'' series addressing the tumoricidal dose of RT for NHLs, investigators noted that a significant number of ''nodular'' lymphomas were controlled with a dose of <22 Gy for >3 years (17,18). However, very few patients were treated with doses <10 Gy.…”

Section: History and Clinical Resultsmentioning

confidence: 96%

“…An increase of infiltrating T cells in the tumor microenvironment and the draining lymphoid tissues was seen 1-2 weeks after treatment. However, a higher radiation dose was used in these experiments (15)(16)(17)(18)(19)(20) Gy in one to four fractions).…”

Section: Potential Systemic Effectsmentioning

confidence: 99%

Localized Low-Dose Radiotherapy for Follicular Lymphoma: History, Clinical Results, Mechanisms of Action, and Future Outlooks

Ganem

Cartron

Girinsky

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Stuschke et al10 recommended a total dose of 30 Gy to lymph nodes with suspected subclinical disease and a total dose of 36–44 Gy to macroscopically involved lymph nodes. Nevertheless, in the “old” series many investigators noted that a significant number of patients with FL were controlled with a dose of <30 Gy 35. These findings led to the design of a randomized phase III study from the United Kingdom, comparing the standard dose of 40–45 Gy to 24 Gy in 361 involved sites of patients with indolent lymphomas (mostly FL and marginal zone B-cell lymphomas -MZL- in early stages) 36.…”

Section: Rt Dosementioning

confidence: 99%

Limited Stage Follicular Lymphoma: The Role of Radiation Therapy.

Filippi

Ciammella²,

Ricardi

2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Radiation therapy (RT) alone has been considered for a long time as the standard therapeutic option for limited stage FL, due to its high efficacy in terms of local disease control with a quite significant proportion of “cured” patients (without further relapses at 10–15 years). Multiple therapeutic choices are currently accepted for the management of early stage FL at diagnosis, and better staging procedures as well as better systemic therapy partially modified the role of RT in this setting. RT has also changed in terms of prescribed dose as well as treatment volumes. In this review, we present and discuss the current role of RT for limited stage FL in light of the historical data and the modern RT concepts along with the possible combination with systemic therapy.

show abstract

On the Question of the Tumoricidal Dose in Non-Hodgkin’s Lymphomas

Cited by 8 publications

References 4 publications

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Localized Low-Dose Radiotherapy for Follicular Lymphoma: History, Clinical Results, Mechanisms of Action, and Future Outlooks

Limited Stage Follicular Lymphoma: The Role of Radiation Therapy.

Contact Info

Product

Resources

About